The biomedical approach to ketamine treatment originated from a randomized controlled trial published in 2000, where seven depressed patients received an intravenous dose of 0.5 mg per kg of bodyweight infused over 40 minutes.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (1)

• ketamine concept